Skip to content
Menu

Iambic Therapeutics, Inc. IAM

Full chart Compare
Set alert

Price alert · IAM

All alert types
13.27 USD -0.99 (-6.94%)

As ofNov 20, 2026, 1:24 PM EST

12.82 Day range 14.00
9.60 52-week range 25.00
YTD
-29.83%
1 year
-29.83%

5D -0.38 (-2.62%)

1214FriMonTueWedThu14.10
Market cap
629.01M
Revenue (ttm)
18.25M
EPS (ttm)
-2.69
Shares out
47.40M
YTD return
-29.83%
1-year return
-29.83%
Volume
143.16K
Avg volume
731.58K
Open
13.98
Previous close
14.26
Day's range
12.82 – 14.00
52-week range
9.60 – 25.00

Key statistics

50-day average
18.91
200-day average
18.91
Enterprise value
637.77M
Price / sales
61.84
Revenue growth
224.70%
Total cash
207.88M
Total debt
5.23M

Fundamental scorecard

4 of 25 checks passed on IAM’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Jun 30, 2026.

Financials — quick view

All financials
IAM Revenue — annual 9.43M
IAM Net income — annual -77.30M
IAM EPS — annual -3.57

About Iambic Therapeutics, Inc.

Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally. It offers products, such as IAM-1363, a selective HER2 inhibitor; IAM-K1, a KIF18A inhibitor; IAM217 (a KIF18A inhibitor) and IAM-C1, a CDK2/4 inhibitor; and services, including drug discovery platform and molecular superintelligence platform which includes technologies, such as Enchant and NeuralPLexer to design and develop small molecule therapeutics. Iambic Therapeutics, Inc. was formerly known as Entos, Inc. and changed its name to Iambic Therapeutics, Inc. in May 2023. The company was incorporated in 2019 and is based in San Diego, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
iambic.ai

News

Your note

Sign in to keep a note on IAM — it syncs with the Stock Master app.